These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8215637)

  • 21. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
    Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival.
    Barth RJ; Camp BJ; Martuscello TA; Dain BJ; Memoli VA
    Cancer; 1996 Sep; 78(6):1168-78. PubMed ID: 8826937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
    Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
    J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
    Stein U; Walther W; Shoemaker RH
    J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.
    Schwartzentruber DJ; Topalian SL; Mancini M; Rosenberg SA
    J Immunol; 1991 May; 146(10):3674-81. PubMed ID: 1902860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
    Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
    Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.
    Sim GC; Chacon J; Haymaker C; Ritthipichai K; Singh M; Hwu P; Radvanyi L
    BioDrugs; 2014 Oct; 28(5):421-37. PubMed ID: 24890028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.
    Fisher B; Packard BS; Read EJ; Carrasquillo JA; Carter CS; Topalian SL; Yang JC; Yolles P; Larson SM; Rosenberg SA
    J Clin Oncol; 1989 Feb; 7(2):250-61. PubMed ID: 2644399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy.
    Itzhaki O; Hovav E; Ziporen Y; Levy D; Kubi A; Zikich D; Hershkovitz L; Treves AJ; Shalmon B; Zippel D; Markel G; Shapira-Frommer R; Schachter J; Besser MJ
    J Immunother; 2011 Mar; 34(2):212-20. PubMed ID: 21304398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
    Kass R; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
    Breast Cancer Res Treat; 2003 Aug; 80(3):275-85. PubMed ID: 14503800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.
    Economou JS; Belldegrun AS; Glaspy J; Toloza EM; Figlin R; Hobbs J; Meldon N; Kaboo R; Tso CL; Miller A; Lau R; McBride W; Moen RC
    J Clin Invest; 1996 Jan; 97(2):515-21. PubMed ID: 8567975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.
    Beane JD; Lee G; Zheng Z; Mendel M; Abate-Daga D; Bharathan M; Black M; Gandhi N; Yu Z; Chandran S; Giedlin M; Ando D; Miller J; Paschon D; Guschin D; Rebar EJ; Reik A; Holmes MC; Gregory PD; Restifo NP; Rosenberg SA; Morgan RA; Feldman SA
    Mol Ther; 2015 Aug; 23(8):1380-1390. PubMed ID: 25939491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.
    Lindenberg M; Retèl V; Rohaan M; van den Berg J; Haanen J; van Harten W
    BMC Cancer; 2020 Jul; 20(1):712. PubMed ID: 32736535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombinant interleukin-2 alone, or with recombinant interleukin-2 and recombinant alpha interferon.
    Hum Gene Ther; 1992 Aug; 3(4):411-30. PubMed ID: 1326336
    [No Abstract]   [Full Text] [Related]  

  • 39. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study.
    Kang WK; Park C; Yoon HL; Kim WS; Yoon SS; Lee MH; Park K; Kim K; Jeong HS; Kim JA; Nam SJ; Yang JH; Son YI; Baek CH; Han J; Ree HJ; Lee ES; Kim SH; Kim DW; Ahn YC; Huh SJ; Choe YH; Lee JH; Park MH; Kong GS; Park EY; Kang YK; Bang YJ; Paik NS; Lee SN; Kim SH; Kim S; Robbins PD; Tahara H; Lotze MT; Park CH
    Hum Gene Ther; 2001 Apr; 12(6):671-84. PubMed ID: 11426466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.
    Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ
    J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.